ALK and non-small cell lung carcinoma: Recently, the eXalt3 phase 3 clinical trial (Clinical Trials.gov Identifier: NCT02767804) investigated the efficacy of China-developed ALK-TKI ensartinib (second-generation) vs. crizotinib in the first-line setting for advanced ALK-positive NSCLC.